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ABSTRACT 
Purpose: to determine the effectiveness of the Aurai water propelled, heating Eye 
Massager (AEM) in managing dry eye disease and its effects on the ocular adnexa.  
Methods: This was a prospective, randomised cross-over study that enrolled 15 
participants (aged 25.8 ± 5.45 years, 5 male). Participants wore a smart watch 24 hours a 
day to track their sleeping cycle and heart rate for 4 weeks, using the AEM twice a day 
for 2 of those weeks. A cycle of 6 minutes of a controlled heat and vibration pattern in 
the morning and another cycle in the evening were applied with the AEM. Primary 
outcomes of symptomatology (Ocular Surface Disease Index (OSDI) and Symptom 
Assessment iN Dry Eye (SANDE)), tear film homeostasis markers (osmolarity, non-
invasive breakup time (NIKBUT), tear meniscus height (TMH), lipid layer thickness and 
ocular staining) and safety measures (ocular redness and intraocular pressure), were 
assessed at baseline, after 2 weeks of AEM use and after 2 weeks of no treatment (in 
random-sequence). Sleeping tracking (ST) and heart rate/blood oxygen detection over 
these periods was also assessed. 
Results: There was a significant change in OSDI score from 34.3±19.5 at baseline to  
18.8±17.5 after treatment (p = 0.001) and also for the SANDE (5.7 ± 2.4 vs 3.7 ± 2.1; p 
= 0.001).  Heart rate was not affected by treatment (p=0.956), nor sleep pattern (p=0.529), 
but this varied by day (p=0.001). Tear film homeostasis, the ocular adnexia and safety 
measures were not affected by treatment (p>0.05). 
Conclusion: The Aurai water propelled Eye Massager may relieve symptoms of dry eye 
and its severity, but there were no detectable effects on tear stability from two weeks use. 
 






Meibomian Gland Dysfunction (MGD) has been defined as the “chronic, diffuse 
abnormality of the meibomian glands, commonly characterized terminal duct obstruction 
and/or qualitative quantitative changes in the glandular secretion. It may result in 
alteration of the tear film, symptoms of eye irritation, clinically apparent inflammation, 
and ocular surface disease”[1]. It is a subset of dry eye disease[2].  
 
As a chronic condition that requires ongoing management, patient compliance has a 
significant impact on treatment efficacy [3, 4]. Many studies have assessed different 
efficacies of lid heating treatments and there is an established relationship between the 
use of eyelid warming devices and improvement of tear film stability and MGD [5]. In 
MGD, the meibum is altered to consist of lower levels of unsaturated fatty acids and non-
polar lipids)[6, 7], raising the melting point, causing the lipid secretions to solidify and 
become inspissated. The mechanism of action appears to be a clearing of the ducts 
through raising the temperature of the glands beyond the melting point of the altered 
meibum, followed by physical massaging of any remaining gland plugs [8]. Many 
management and therapy options had been developed to warm the lids. Such treatments 
include infrared devices [8, 9], warm compresses [10, 11], disposable eyelid warming 
devices [12] and warm moist air devices [13]. The efficacy of warm compresses are 
presented in Table 1 [10, 12-24]. Studies regarding what the most optimal temperature to 
melt the meibum of the glands might be suggest reasonable variability[25], perhaps 
greater in patients with MGD[26], affecting the efficacy of lid warming treatments.are in 
place [27, 28]. Massaging in general has many health benefits and few known risks, so 
could massage of the eyelids and adnexia benefit sleep or blood circulation?[29] Hence, 
new approaches to lid warming and massage are of great interest to manage this chronic, 
debilitating condition. 
 
The aim of this study was to investigate the efficacy of a novel water propelled eyelid 





This prospective, randomised cross-over trial adhered to the tenets of the Declaration of 
Helsinki and was given a favourable opinion by Aston University Ethics Committee and 
governance approval. It was registered as a clinical trial on www.researchregistry.com 
UIN #5167.   
 
Participants were required to be 18 years or older with a positive diagnosis of dry eye 
disease (DED) using the diagnostic criteria of TFOS DEWS II (symptoms of dry eye ≥13 
on the Ocular Surface Disease Index (OSDI) and at least one of the global 
signs/homeostasis markers)[30]. Exclusion criteria included use of contact lenses, current 
eyelid warming therapies, current artificial drop use, ocular pathologies (excluding 
blepharitis and MGD) and systemic issues such as diabetes and inflammatory conditions). 
Prior to commencement participants had signed the informed consent and were enrolled 
if eligible. Fifteen participants were (67% female, age 25.8 ± 5.45 years, range 20-37 
years) recruited, based on the minimum sample size recommendation for repeated 
measure analysis of variance [31]. This number of participants has also been shown to be 
adequate to detect a clinically significant difference for the inter-group comparisons at 
80% power with an alpha of 0.05 [30, 32]. Data were measured from the right eye only 
except for osmolarity where the highest value between the eyes are recommended 
variables. All participants had had DED for at least 2 years  
 
The baseline measurements, conducted in the following order, were: OSDI; Symptom 
Assessment iN Dry Eye (SANDE)[33]; Osmolarity, highest value from 2 eyes collected 
from the lower meniscus [34] using a TearLab station (TearLab Ltd, California, USA) 
with calibration performed every day following the manufacturer’s instructions and 
TearLab chips were placed beside the station for humidity and temperature regulation; 
Ocular Hyperaemia in the nasal and temporal bulbar and limbal regions (OH); Tear 
meniscus height (TMH) illuminated with infrared light, calculated from a calibrated 
digital image; Non-Invasive Breakup Time (NIKBUT) - average of 3 readings after two 
non-forceful blinks; and Lipid layer thickness (LLT) evaluated by tear film interferometry 
and graded as: 0 (absent), 1 (open meshwork), 2 (closed meshwork), 3 (wave), 4 
(amorphous), or 5 (coloured fringes), all evaluated objectively (except LLT) using the 




Ocular staining with fluorescein, corneal staining (CornS) was assessed by wetting a 
fluorescein strip with saline, shaking off the excess, and instilling it at the outer canthus. 
Lissamine green, conjunctival staining (ConjS), was assessed by wetting a Lissamine 
strip (GreenGlo, HUB Pharmaceuticals, LLC, Rancho Cucamonga, California, USA) 
with a single drop of saline solution, keeping the drop on the strip for 5 seconds to elude 
the dye, and instilling it at the outer canthus. Assessment was performed with a slit lamp 
and the number of punctate spots counted[30]. 
 
The Aurai Eye Massager (AEM) has an integral silicon mask which contains water which 
can be warmed/cooled and vibrated (Figure 1). The water-propelled massager is marketed 
as relaxing muscular tension around the eyes, to improve blood circulation and relaxation. 
All measurements were performed by the same clinician in the same order. The 
assessment was conducted in a room where temperature and humidity remained constant 
between 20-22°C and 30-45% respectively, to ensure that the measurements were not 
affected by ambient humidity. Participants spent a minimum of 10 min acclimatising to 
the room conditions before being tested as factors such as humidity can affect 
measurements [36]. 
 
Participants were required to wear a watch (IP68 Fitness Activity Tracker, Smart Watch, 
Teepao.com), 24h a day, which captured Heart Rate and Blood Oxygen (O2 – using red 
and infra-red light pulse oximetry) and sleeping time (ST – through inactivity of 
movement). All participants wore the watch for 4 weeks; for 2 weeks no intervention was 
undertaken (control condition) and for the other 2 weeks, participants were instructed to 
use the AEM 6 minutes twice daily, using the warm and vibration cycle as recommended 
in the manufacturers instructions. The AEM warms to 40℃ +3/-2℃  within 2 minutes 
and remains at this temperature for the rest of the 6 minute vibration cycle. The order of 
the control condition and AEM treatment was randomised between participants. After 
each two weeks participants returned and the measures captured at baseline were repeated 
by a masked researcher. Participants were not masked due to the appearance of the device 
and the physical sensation. After returning the AEM, participants were asked how often 
they had used the AEM. Patient compliance was recorded (number of times the system 




Heart rate, Blood Oxygen (O2) and Sleeping Time (ST) were gathered from the watch. 
Intraocular pressure was measured at each visit with Ocular Response Analyser (ORA) 
(Reichert Technologies, Germany). In addition, IOP was measures before and at minute 
intervals after eye massager use for 3 minutes at the end of the study to examine for any 
immediate pressure spikes. 
 
Figure 1: AURAI Mask Massager 
Data analysis 
Statistical analysis was performed using IBM SPSS Statistics version 25 (New York, 
USA). The distributions of the data was assessed using one-sample Kolmogorov-Smirnov 
test. Symptomology, intraocular pressure, heart rate, blood oxygen and sleeping time 
were found to be normally distributed and therefore analysed with a repeated measured 
Analysis of Variance, while the other metrics were assessed with a related sample 







All participants completed the study and reported good compliance (a maximum of one 
missed treatment). They had mild to moderate symptoms (Table 2) and had had DED for 
at least 2 years. 
Summary statistics of clinical measurements at baseline, after 2 weeks of no treatment, 
and 2 weeks post-treatment are presented in Table 2. Dry eye symptoms decreased with 
treatment (OSDI and SANDE severity metric; p<0.001). Interestingly, there was an 
apparent placebo effect of just wearing the fitness monitoring watch (OSDI: p=0.042; 
SANDE severity; p=0.006).  
 
Table 2: Measurement Pre and post treatment. Average ± SD or median (range) of dry 
eye symptoms and signs at baseline, after 2 weeks of watch control, and after 2 weeks of 
treatment. N=15. SANDE = Symptom Assessment in Dry Eye (consisting of a frequency 
of symptoms and severity of symptoms visual analogue scale), TMH = Tear Meniscus 
Height, NIKBUT = Non-Invasive Keratometric Break-Up Time, LLT = Lipid Layer 
Thickness, IOP = Intra Ocular Pressure, , O2 = Blood Oxygen, ST = Sleeping Time 
 Baseline Post control 
period 
Post AEM Significance 
(p-value) 
OSDI  34.3±19.5 26.5±19.8 18.8±17.5 0.001 
SANDE Frequency 4.05±2.20 4.03±2.46 2.55±1.61 0.262 
SANDE Severity 5.70±2.43 4.35±2.40 3.65±2.12 0.001 
Osmolarity 
(mOsm/l) 
293 (284-348) 291 (285-312) 291 (280-307) 0.888 
Bulbar redness 
temporal (grade) 
0.6 (0.0-1.1) 0.5 (0.3-1.5) 0.6 (0.4-0.8) 0.534 
Bulbar redness 
nasal (grade) 
0.6 (0.4-1.7) 0.6 (0.3-2.1) 0.5 (0.0-1.7) 0.775 
Limbal redness 
temporal (grade) 
0.3 (0.0-1.1) 0.3 (0.0-1.4) 0.3 (0.2-1.7) 0.971 
Limbal redness 
nasal (grade) 
0.4 (0.2-0.7) 0.4 (0.2-2.0) 0.3 (0.2-0.6) 0.472 
TMH (mm) 0.22 (0.12-0.63) 0.24 (0.11-0.45) 0.23 (0.13-0.42) 0.247 
NIKBUT (s) 6.3 (4.2-10.8) 5.4 (3.8-13.7) 5.3 (1.0-12.7) 0.430 
LLT (grade) 2.0 (1.0-3.0) 2.0 (1.0-3.0) 2.0 (1.0-3.0) 0.975 
Corneal staining 
(grade) 
0.0 (0.0-3.0) 0.0 (0.0-3.0) 0.0 (0.0-1.0) 0.949 
Conjunctival 
staining (grade) 
1.0 (0.0-3.0) 1.0 (0.0-3.0) 1.0 (0.0-3.0) 0.575 
Lid margin staining 
(grade) 
1.0 (0.0-3.0) 1.0 (0.0-3.0) 1.0 (0.0-3.0) 0.298 
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IOP (mmHg) 13.91±1.89 13.29±2.02 13.83±2.59 0.349 
Heart rate (beats 
per minute) 
N/A 81.33±9.16 81.10±9.84 0.828 
O2 (%) N/A 98.87±36.11 97.37±3.69 0.268 
ST (hours) N/A 6.94±1.89 7.38±1.30 0.529 
 
Intraocular pressure did increase immediately after use of the AEM (F=4.113, p=0.017) 
by 1.5 ± 2.0 mmHg, but this reduced rapidly (difference from baseline: 2 minutes, +1.3 ± 






This study investigated the efficacy of a novel water propelled eyelid automated warming 
device after 2 weeks use in patients with dry eye disease. The OSDI scores at baseline 
ranged from 13 to 66 indicating mild to moderate DED severity. Two weeks use, twice a 
day, has previously been shown to be an effective duration of treatment of the meibomian 
glands to observe improvements in symptoms and signs such as tear stability, lipid layer 
thickness and meibomian gland expressability, but generally not ocular surface staining 
or meibomian gland drop-out (Table 1)[10, 12-24]. Several studies have shown 
immediate patient benefit from even a single session of eyelid warming [10, 20, 37] 
including in non-dry eye individuals [4, 11], making this an attractive treatment option. 
 
There was a clear reduction on symptoms having used the AEM device for 2 weeks. The 
improvement of 15.5 points on the OSDI is comparable with previously reported warm 
compress studies (Table 1). Comfort was the only subjective measure and in the repeated-
measures design it also appeared to improve in the period when there was no treatment 
(the control condition), hence a possible ‘placebo’ effect of being monitored. However, 
when just the participants who were randomised to have the no treatment period 
monitoring before using the AEM device are considered, no improvement in symptoms 
was seen (the difference in symptomatology was only -0.4±6.5 for the OSDI and 0.1±1.6 
for the SANDE Severity score [minus indicates worsening symptoms]); this suggests that 
the improvement in symptoms following use of the AEM was a real and sustained effect, 
as the participant randomised to use the AEM device first followed by 2 weeks of no 
treatment had little reason to believe that the benefit in symptomatology would occur even 
when assessed two week after last using the device. Compliance was reported as being 
good by all participants which may have been aided by the reduction in symptoms 
resulting from the AEM use. 
 
Unlike previous studies (Table 1), no improvement was seen in ocular surface signs. It is 
well known that the signs & symptoms of dry eye disease do not correlate well [38], 
however the finding does not allow the mechanism of the improvement in symptoms to 
be explained. Perhaps the massaging of the skin around the eyes might be contributing to 




Previous studies had not looked at other possible general health benefits such as improved 
lower levels of stress as indicated by heart rate, blood oxygen and sleep duration (Table 
1). Most participants, unprompted, reported a feeling of being relaxed after the use of the 
mask, but the number of hours to sleep prior or after the use of AEM did not change 
statistically. In this study, no difference was seen in these possible general health benefits, 
but that might be because of the short-term use of the eye mask. Future longer duration 
studies could examine these potential general health benefits more in depth. It is known 
that rubbing the eyes can increase the IOP [39]; the lack of any change seen on this study 
suggests that there are no immediate or long-term safety concerns from the massaging 
action.  
 
In conclusion a considerable improvement in subjective symptom severity has been 
shown after the use of the AEM device, sustained over at least 2 weeks, even though no 
improvement in clinical signs were detectable in this study. Further randomised studies 
with longer term use of the AEM are required to fully explore the potential benefit of 
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Table 1: Comparison of dispensing warm compress efficacy studies. Symptom improvement reported for dry eye group from warm compress 
therapy. MGD meibomian gland dysfunction; IPL intense pulse light therapy; LLT lipid layer thickness; NIBUT non-invasive breakup time; TBUT fluorescein 
tear breakup time; MG meibomian gland; OSDI ocular surface disease index; SANDE symptom assessment in dry; SPEED standard patient evaluation of eye 
dryness;  DEQS dry eye–related quality-of-life score; TMH tear meniscus height; IOP intraocular pressure. 
 
Study Participants Warm 
Compress 














Warm face cloth 8 weeks, 10 min 
2x/day for 2 
weeks 
MG quality & expressability, 
Demodex (OPTASE only)  
 
-23.1 from 39.8 
OSDI Eyebag 




Schirmer I test 
Face cloth cohort OSDI 
baseline was 24 vs 40 in 










2 weeks, 10 min a 
day  










lens dry eye 
Bruder moist 
heat compress 
Single vs two 
applications vs 
washcloth 
4 weeks, 10 min 
applications 
Comfortable wear time and MG 
expressability with Bruder mask 
regardless of frequency of use 
-8.9 from 22.9 
OSDI 1x/day, -











4 weeks, 10 min 
compress nightly 
TBUT, MG expressability (1 
month) and cytokines (1 wk) 
with IPL  





Warm compress not as good as 
IPL 







24 dry eye, 
12 in 
extension 
Heat mask Tearcare system 4 weeks, 5 min 
daily followed up 
after 6 months 
TBUT, MG expression, corneal 
& conjunctival staining with 
Tearcare, worsening TBUT with 
heat mask 
-8.4 from 33.0 
OSDI. SPEED 
& SANDE also 
improved 
None reported No changes in IOP at 6 months. 
Tearcare retreatment at 6 
months boosted benefits. Sole 





35 dry eye, 
20 controls 
Heat mask Contralateral 
eyelid with or 
without menthol 
2 weeks, 10 min 
2x/day  
MG quality improved in all 
patients, but TMH and TBUT 
only increased with menthol 
mask 
-25.5 from 49.7 
with heat, -17.8 
from 41.0 with 
Corneal staining Effects were also seen after a 
single 10 min application 
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50 dry eye Washcloth & 
lid scrubs n=25 
Lipiflow n=25 12 weeks, 2x/day 
vs single session 
Lipiflow 
TBUT (at 4 but not 12 weeks) in 
both groups, Schirmers in the 
washcloth group, MG expression 
(only examined in Lipiflow 
group) 





Not randomised & baseline 
staining higher in washcloth 
group. Lid hygiene encourage 
in both group. Duration of 
warm compress and frequency 




200  MGD 
dry eye 
Warm 
compress & lid 
hygiene n=99 
Lipiflow n=99 12 weeks, 10 min 
2x/day vs single 
session Lipiflow  
MG expression greater with 
Lipiflow 
-17.8 from 51.8 
OSDI 
None reported Lipiflow followed for up to 12 
months and positive benefit 
still apparent. Baseline OSDI 





50 MGD Warm 
compress 
Blephasteam 3 weeks warm 
compress 10 min 
2x/day followed 
by 3 weeks 
Blephasteam  
18 had no improvement in BUT 
or acinar diameter with warm 
compress, but did with 
Blephasteam. No further  
improvement in warm compress 
responders 
-13.6 from 36.3 
OSDI in n=32 
responders; ~-
8.7 across all 
patients 
None reported Corneal staining, Schirmer * 
MG expression in 










2 weeks, 5 min 
2x/day followed 
for 6 months 
NIBUT, LLT, osmolarity, 
MG dropout and expression, 
hyperaemia and staining 
-33.0 from 52.5 
scaled to 100 
Visual acuity & 
corneal 
topography 
Improvement in OSDI from 











MG expression and TBUT only 
with Lipiflow;  










to et al., 
2006 [13] 
10 MGD, 10 
controls 
Warm moist air 
compress 
Hot towel 2 weeks, 10 min 
2x/day 
LLT (more with warm moist 
compress) TBUT (warm moist 
compress only) 
-53.8 from 77.3 
in ocular fatigue 









- 2 weeks, 5 min 
2x/day 
BUT, LLT, MG expressability -24 from 52 
scaled to 100 
None reported  
 
